Chronotherapy for Radiotherapy of Glioma

Sponsor
General Hospital of Ningxia Medical University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04735939
Collaborator
(none)
80
1
10.9
7.3

Study Details

Study Description

Brief Summary

This study aims to determine if there is any difference in the efficacy of radiotherapy for glioma outcomes in the morning or in the evening. The study team believes that there may be a benefit to taking the radiotherapy at a certain time of day. To test this theory the study asks participants who are already taking radiotherapy for glioma consistently at either the morning or in the evening based on when they currently take their radiotherapy. There will be this study visits where the participant will be asked to fill in questionnaires related to their neurological symptoms, their sleep habits, sleep quality, survival situation, and general health information followed by a blood draw.

Condition or Disease Intervention/Treatment Phase
  • Radiation: radiotherapy

Detailed Description

The objective of this study is to determine whether the timing of radiotherapy to treat glioma has an effect on patient outcomes.

Primary objective: Determine whether there is a difference in outcomes seen when patients are assigned to take their radiotherapy at either a morning time or evening time.

The Investigator hypothesize that administration time of radiotherapy during the day can affect the clinical outcomes in glioma patients.

Specific Aims Include:
  • Determine whether morning vs. evening dosing radiotherapy could affect the survival time of glioma patients.

  • Determine whether morning vs. evening dosing radiotherapy could affect the KPS score of glioma patients.

  • Determine whether morning vs. evening dosing radiotherapy could affect the cognitive function of glioma patients.

Study Design

Study Type:
Observational
Anticipated Enrollment :
80 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Chronotherapy for Radiotherapy of Glioma
Anticipated Study Start Date :
Feb 1, 2021
Anticipated Primary Completion Date :
Dec 31, 2021
Anticipated Study Completion Date :
Dec 31, 2021

Arms and Interventions

Arm Intervention/Treatment
morning dosing radiotherapy

Radiation: radiotherapy
Determine whether there is a difference in outcomes seen when patients are assigned to take their radiotherapy at either a morning time or evening time.

evening dosing radiotherapy

Radiation: radiotherapy
Determine whether there is a difference in outcomes seen when patients are assigned to take their radiotherapy at either a morning time or evening time.

Outcome Measures

Primary Outcome Measures

  1. survival time of glioma patients [1/1/2021-31/12/2021]

    Determine whether morning vs. evening dosing radiotherapy could affect the survival time of glioma patients.

Secondary Outcome Measures

  1. KPS score of glioma patients. [1/1/2021-31/12/2021]

    Determine whether morning vs. evening dosing radiotherapy could affect the KPS score of glioma patients.

Other Outcome Measures

  1. cognitive function of glioma patients [1/1/2021-31/12/2021]

    Determine whether morning vs. evening dosing radiotherapy could affect the cognitive function of glioma patients.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Age ≥ 18 years;

  2. Pathological or cytological diagnosis of glioma;

  3. Normal liver and kidney function.

Exclusion Criteria:
  1. Pregnant or lactating women;

  2. Second primary malignancy;

  3. Severe lung infection;

  4. with high blood pressure although treated with medication;

  5. Patients with myocardial ischemia or myocardial infarction, arrhythmia (including QT interval > 440 ms) or grade II cardiac insufficiency;

  6. Arteriovenous thrombosis in 6 months prior to first administration, Such as cerebrovascular accident (including temporary ischemic attack), deep vein thrombosis and pulmonary embolism;

  7. Serious heart, lung and bone marrow impairment;

  8. History of severe hypertension or cerebral hemorrhage

Contacts and Locations

Locations

Site City State Country Postal Code
1 General Hospital of Ningxia Medical University Yinchuan Ningxia China 750004

Sponsors and Collaborators

  • General Hospital of Ningxia Medical University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
General Hospital of Ningxia Medical University
ClinicalTrials.gov Identifier:
NCT04735939
Other Study ID Numbers:
  • xhechun5
First Posted:
Feb 3, 2021
Last Update Posted:
Feb 3, 2021
Last Verified:
Jan 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by General Hospital of Ningxia Medical University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 3, 2021